Some sponsors are enjoying an extra serving of regulatory cranberry sauce this week after their development programs received a breakthrough therapy designation (BTD) from the US FDA.
COMPASS Pathways announced a breakthrough therapy designation Oct. 23 for its treatment-resistant depression candidate psilocybin, reflecting a growing trend of...






